These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34473191)

  • 21. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic.
    Sughayer MA; Mansour A; Al Nuirat A; Souan L; Ghanem M; Siag M
    Int J Infect Dis; 2021 Jun; 107():116-120. PubMed ID: 33892190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors.
    Razafimahatratra SL; Ndiaye MDB; Rasoloharimanana LT; Dussart P; Sahondranirina PH; Randriamanantany ZA; Schoenhals M
    Lancet Glob Health; 2021 Oct; 9(10):e1363-e1364. PubMed ID: 34534478
    [No Abstract]   [Full Text] [Related]  

  • 24. Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients.
    Del Zompo F; De Maio F; Santopaolo F; Ricci R; Gasbarrini A; Pompili M; Ponziani FR
    Dig Liver Dis; 2021 May; 53(5):541-544. PubMed ID: 33707148
    [No Abstract]   [Full Text] [Related]  

  • 25. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers in a nonepidemic region, Japan: A hospital-based study on May, 2020.
    Nakamura A; Ando S; Endo H; Sato R
    J Med Virol; 2021 Jul; 93(7):4608-4611. PubMed ID: 33760273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area.
    Cassaniti I; Percivalle E; Sarasini A; Cambiè G; Vecchio Nepita E; Maserati R; Ferrari A; Corcione A; Di Martino R; Bonetti A; Di Napoli A; Ferrari G; Baldanti F
    Clin Microbiol Infect; 2021 Jun; 27(6):914.e1-914.e4. PubMed ID: 33677083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
    Rathe JA; Hemann EA; Eggenberger J; Li Z; Knoll ML; Stokes C; Hsiang TY; Netland J; Takehara KK; Pepper M; Gale M
    J Infect Dis; 2021 Apr; 223(7):1120-1131. PubMed ID: 33367830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran.
    Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M
    Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
    Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study.
    Lewin A; Therrien R; De Serres G; Grégoire Y; Perreault J; Drouin M; Fournier MJ; Tremblay T; Beaudoin J; Beaudoin-Bussières G; Prévost J; Gendron-Lepage G; Finzi A; Bernier F; Bazin R; Germain M; Delage G
    Can J Public Health; 2021 Aug; 112(4):576-586. PubMed ID: 33999398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
    Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel.
    Reicher S; Ratzon R; Ben-Sahar S; Hermoni-Alon S; Mossinson D; Shenhar Y; Friger M; Lustig Y; Alroy-Preis S; Anis E; Sadetzki S; Kaliner E
    Eur J Epidemiol; 2021 Jul; 36(7):727-734. PubMed ID: 33884542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of COVID-19 Virus Infection in Semnan province.
    Jandaghi E; Hemati M; Mohammadlou M; Jandaghi J; Mirmohammadkhani M; Danaei N; Kokhaei P
    Iran J Immunol; 2021 Mar; 18(1):74-81. PubMed ID: 33787516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting.
    Müller L; Ostermann PN; Walker A; Wienemann T; Mertens A; Adams O; Andree M; Hauka S; Lübke N; Keitel V; Drexler I; Di Cristanziano V; Hermsen DF; Kaiser R; Boege F; Klein F; Schaal H; Timm J; Senff T
    Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):1063-1071. PubMed ID: 33534090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
    Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
    PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
    Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D;
    Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of SARS-COV-2 positivity in 516 German intensive care and emergency physicians studied by seroprevalence of antibodies National Covid Survey Germany (NAT-COV-SURV).
    Kindgen-Milles D; Brandenburger T; Braun JFW; Cleff C; Moussazadeh K; Mrosewski I; Timm J; Wetzchewald D
    PLoS One; 2021; 16(4):e0248813. PubMed ID: 33831032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.